Top

Published in:

01-08-2018 | Review

Percutaneous coronary intervention: balloons, stents and scaffolds

Authors: Roisin Colleran, Adnan Kastrati

Published in: Clinical Research in Cardiology | Special Issue 2/2018

Abstract

In this review, major achievements in the field of percutaneous coronary interventions are delineated with particular focus on Germany’s contribution. The review deals with important developments, including the first heart catheterization and coronary angiography, first coronary balloon angioplasty and refinement of the technique, coronary stenting and optimization of adjunctive antithrombotic treatment, drug-eluting stents and balloons, as well as bioresorbable polymeric and metallic drug-eluting scaffolds.

King SB 3rd (1998) The development of interventional cardiology. J Am Coll Cardiol 31:64b–88bCrossRefPubMed

Wierny L, Plass R, Porstmann W (1974) Long-term results in 100 consecutive patients treated by transluminal angioplasty. Radiology 112:543–548CrossRefPubMed

Kaltenbach M (2002) Evolution of interventional cardiology in Germany. J Interv Cardiol 15:33–39CrossRefPubMed

Simpson JB, Baim DS, Robert EW, Harrison DC (1982) A new catheter system for coronary angioplasty. Am J Cardiol 49:1216–1222CrossRefPubMed

Kaltenbach M (1984) The long wire technique—a new technique for steerable balloon catheter dilatation of coronary artery stenoses. Eur Heart J 5:1004–1009CrossRefPubMed

Bonzel T, Wollschläger H, Just H (1986) A new catheter system for the mechanical dilatation of coronary stenoses with exchangeable intracoronary catheters, fast flow of the contrast agent and improved control. Biomed Tech 31:195–200CrossRef

Byrne RA, Stone GW, Ormiston J, Kastrati A (2017) Coronary balloon angioplasty, stents, and scaffolds. Lancet 390:781–792CrossRefPubMed

Byrne RA, Joner M, Kastrati A (2015) Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J 36:3320–3331

Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316:701–706CrossRefPubMed

10.

Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214CrossRefPubMed

11.

Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489–495CrossRefPubMed

12.

Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331:496–501CrossRefPubMed

13.

Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089CrossRefPubMed

14.

Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schuhlen H, Pache J et al (2000) Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv 50:290–297CrossRefPubMed

15.

Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL et al (2011) Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123:1400–1409CrossRefPubMedPubMedCentral

16.

Simon C, Palmaz JC, Sprague EA (2000) Influence of topography on endothelialization of stents: clues for new designs. J Long Term Effects Med Implants 10:143–151CrossRef

17.

Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ et al (2001) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103:2816–2821CrossRefPubMed

18.

Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J et al (2003) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41:1283–1288CrossRefPubMed

19.

Schulz S, Mehilli J, Schomig A, Kastrati A (2010) ISAR—a story of trials with impact on practice. Circ J 74:1771–1778CrossRefPubMed

20.

Palmaz JC, Benson A, Sprague EA (1999) Influence of surface topography on endothelialization of intravascular metallic material. J Vasc Interv Radiol 10:439–444CrossRefPubMed

21.

Nakayama Y, Nishi S, Ishibashi-Ueda H, Matsuda T (2000) Surface microarchitectural design in biomedical applications: in vivo analysis of tissue ingrowth in excimer laser-directed micropored scaffold for cardiovascular tissue engineering. J Biomed Mater Res 51:520–528CrossRefPubMed

22.

Dibra A, Kastrati A, Mehilli J, Pache J, von Oepen R, Dirschinger J et al (2005) Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial. Catheter Cardiovasc Interv 65:374–380CrossRefPubMed

23.

Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780CrossRefPubMed

24.

Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT et al (2004) One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942–1947CrossRefPubMed

25.

Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202CrossRefPubMed

26.

Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A et al (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948CrossRefPubMed

27.

Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S et al (2005) Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 25:748–753CrossRefPubMed

28.

Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T et al (2005) Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 26:1475–1481CrossRefPubMed

29.

Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O et al (2008) Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 29:1975–1982CrossRefPubMed

30.

Desch S, Schloma D, Mobius-Winkler S, Erbs S, Gielen S, Linke A et al (2011) Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial. JACC Cardiovasc Interv 4:452–459CrossRefPubMed

31.

Steigerwald K, Merl S, Kastrati A, Wieczorek A, Vorpahl M, Mannhold R et al (2009) The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials 30:632–637CrossRefPubMed

32.

Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL et al (2009) Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 30:2441–2449CrossRefPubMed

33.

Kufner S, Byrne RA, Valeskini M, Schulz S, Ibrahim T, Hoppmann P et al (2016) Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. EuroIntervention 11:1372–1379CrossRefPubMed

34.

Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A et al (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372:1163–1173CrossRefPubMed

35.

Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A et al (2011) Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378:1940–1948CrossRefPubMed

36.

Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S et al (2012) Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 33:1214–1222CrossRefPubMed

37.

Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S et al (1997) Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 337:365–372CrossRefPubMed

38.

Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J et al (2011) Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation 124:624–632CrossRefPubMed

39.

Kufner S, Sorges J, Mehilli J, Cassese S, Repp J, Wiebe J et al (2016) Randomized trial of polymer-free sirolimus- and probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-year results of the ISAR-TEST-5 Trial. JACC Cardiovasc Interv 9:784–792CrossRefPubMed

40.

Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S et al (2015) Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J 36:2608–2620CrossRefPubMed

41.

Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M et al (1997) Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30:1428–1436CrossRefPubMed

42.

Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A (1999) Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 83:1617–1622CrossRefPubMed

43.

Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T et al (2014) Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 100:153–159CrossRefPubMed

44.

Cassese S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, Feuchtenberger A et al (2015) Prognostic role of restenosis in 10,004 patients undergoing routine control angiography after coronary stenting. Eur Heart J 36:94–99CrossRefPubMed

45.

Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G (2003) Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 42:1415–1420CrossRefPubMed

46.

Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Bohm M et al (2003) Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 24:1462–1467CrossRefPubMed

47.

Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O (2004) Inhibition of restenosis in stented porcine coronary arteries: uptake of paclitaxel from angiographic contrast media. Investig Radiol 39:182–186CrossRef

48.

Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G (2004) Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110:810–814CrossRefPubMed

49.

Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124CrossRefPubMed

50.

Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K et al (2013) Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 381:461–467CrossRefPubMed

51.

Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia del B, Blanco A, Garcia-Touchard JR, Lopez-Minguez et al (2015) A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol 66:23–33CrossRefPubMed

52.

Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ et al (2015) Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 386:655–664CrossRefPubMed

53.

Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRefPubMed

54.

Kleber FX, Rittger H, Ludwig J, Schulz A, Mathey DG, Boxberger M et al (2016) Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial. Clin Res Cardiol 105:613–621CrossRef

55.

Adriaenssens T, Byrne R (2014) PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort: PRESTIGE. Eur Heart J 35:2128–2129PubMed

56.

Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E et al (2017) Optical coherence tomography findings in patients with coronary stent thrombosis: a Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 136:1007–1021CrossRefPubMedPubMedCentral

57.

Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J et al (2015) Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet 387:537–544

58.

Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ et al (2017) 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet 390:760–772CrossRefPubMed

59.

Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS et al (2017) 3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III Trial. J Am Coll Cardiol 70:2852–2862CrossRefPubMed

60.

Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ et al (2016) Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 388:2479–2491CrossRefPubMed

61.

Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ et al (2017) Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med 376:2319–2328CrossRefPubMed

62.

Sanchez OD, Yahagi K, Byrne RA, Mori H, Zarpak R, Wittchow E et al (2015) Pathological aspects of bioresorbable stent implantation. EuroIntervention 11(Suppl V):V159–V165

63.

Raber L, Brugaletta S, Yamaji K, O’Sullivan CJ, Otsuki S, Koppara T et al (2015) Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol 66:1901–1914CrossRefPubMed

64.

Fajadet J, Haude M, Joner M, Koolen J, Lee M, Tolg R et al (2016) Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016. EuroIntervention 12:828–833CrossRefPubMed

65.

Erbel R, Mario CD, Bartunek J, Bonnier J, de Bruyne B, Eberli FR et al (2007) Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369:1869–1875CrossRefPubMed

66.

Haude M, Erbel R, Erne P, Verheye S, Degen H, Bose D et al (2013) Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 381:836–844CrossRefPubMed

67.

Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C et al (2016) Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet 387:31–39CrossRefPubMed

Title: Percutaneous coronary intervention: balloons, stents and scaffolds
Authors: Roisin Colleran
Adnan Kastrati
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue Special Issue 2/2018
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-018-1328-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Percutaneous coronary intervention: balloons, stents and scaffolds

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2018

Atrioventricular valve disease: challenges and achievements in percutaneous treatment

German contribution to development and innovations in the management of acute myocardial infarction and cardiogenic shock

Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University

Therapeutic options in advanced heart failure

Hypertension: history and development of established and novel treatments

Progress in heart failure treatment in Germany

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page